Stay updated on IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial page.

Latest updates to the IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded a government-operating-status notice and new version v3.2.0; removed old version v3.1.0.SummaryDifference3%
- Check21 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.1%
- Check28 days agoNo Change Detected
- Check36 days agoChange DetectedUpdated revision from v3.0.1 to v3.0.2. Removed the 'Back to Top' element.SummaryDifference0.2%
- Check43 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.2%
- Check50 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, while key drug names such as Mirvetuximab Soravtansine and Pembrolizumab have been removed.SummaryDifference1%
- Check64 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial page.